Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 200 of 257

1.

The FLUENT study design: investigating immune cell subset and neurofilament changes in patients with relapsing multiple sclerosis treated with fingolimod.

Cohen JA, Bar-Or A, Cree BAC, Mao-Draayer Y, Han MH, Singer B, Jannu A, Kolodny S, Meng X, Winger RC.

Mult Scler J Exp Transl Clin. 2019 Jan 2;5(1):2055217318819245. doi: 10.1177/2055217318819245. eCollection 2019 Jan-Mar.

2.

Recirculating Intestinal IgA-Producing Cells Regulate Neuroinflammation via IL-10.

Rojas OL, Pröbstel AK, Porfilio EA, Wang AA, Charabati M, Sun T, Lee DSW, Galicia G, Ramaglia V, Ward LA, Leung LYT, Najafi G, Khaleghi K, Garcillán B, Li A, Besla R, Naouar I, Cao EY, Chiaranunt P, Burrows K, Robinson HG, Allanach JR, Yam J, Luck H, Campbell DJ, Allman D, Brooks DG, Tomura M, Baumann R, Zamvil SS, Bar-Or A, Horwitz MS, Winer DA, Mortha A, Mackay F, Prat A, Osborne LC, Robbins C, Baranzini SE, Gommerman JL.

Cell. 2018 Dec 21. pii: S0092-8674(18)31560-5. doi: 10.1016/j.cell.2018.11.035. [Epub ahead of print]

PMID:
30612739
3.

Author Correction: Multiple sclerosis.

Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, Rocca MA.

Nat Rev Dis Primers. 2018 Nov 22;4(1):49. doi: 10.1038/s41572-018-0050-3.

PMID:
30467372
4.

Author Correction: Neuroimmune disorders of the central nervous system in children in the molecular era.

Wells E, Hacohen Y, Waldman A, Tillema JM, Soldatos A, Ances B, Benseler S, Bielekova B, Dale RC, Dalmau J, Gaillard W, Gorman M, Greenberg B, Hyslop A, Pardo CA, Tasker RC, Yeh EA, Bar-Or A, Pittock S, Vanderver A, Banwell B; attendees of the International Neuroimmune Meeting.

Nat Rev Neurol. 2018 Dec;14(12):749. doi: 10.1038/s41582-018-0077-9.

PMID:
30442924
5.

A tyrosine sulfation-dependent HLA-I modification identifies memory B cells and plasma cells.

Chan JTH, Liu Y, Khan S, St-Germain JR, Zou C, Leung LYT, Yang J, Shi M, Grunebaum E, Campisi P, Propst EJ, Holler T, Bar-Or A, Wither JE, Cairo CW, Moran MF, Palazzo AF, Cooper MD, Ehrhardt GRA.

Sci Adv. 2018 Nov 7;4(11):eaar7653. doi: 10.1126/sciadv.aar7653. eCollection 2018 Nov.

6.

Multiple sclerosis.

Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, Rocca MA.

Nat Rev Dis Primers. 2018 Nov 8;4(1):43. doi: 10.1038/s41572-018-0041-4. Review. Erratum in: Nat Rev Dis Primers. 2018 Nov 22;4(1):49.

PMID:
30410033
7.

Incidence and prevalence of MS in children: A population-based study in Ontario, Canada.

Marrie RA, O'Mahony J, Maxwell C, Ling V, Yeh EA, Arnold DL, Bar-Or A, Banwell B; Canadian Pediatric Demyelinating Disease Network.

Neurology. 2018 Oct 23;91(17):e1579-e1590. doi: 10.1212/WNL.0000000000006395. Epub 2018 Sep 26.

PMID:
30258022
8.

Physical activity and dentate gyrus volume in pediatric acquired demyelinating syndromes.

Longoni G, Brown RA, Aubert-Broche B, Grover SA, Branson HM, Fetco D, Bar-Or A, Marrie RA, Motl RW, Collins DL, Narayanan S, Arnold DL, Banwell B, Yeh EA.

Neurol Neuroimmunol Neuroinflamm. 2018 Sep 6;5(6):e499. doi: 10.1212/NXI.0000000000000499. eCollection 2018 Nov.

9.

Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.

Chitnis T, Arnold DL, Banwell B, Brück W, Ghezzi A, Giovannoni G, Greenberg B, Krupp L, Rostásy K, Tardieu M, Waubant E, Wolinsky JS, Bar-Or A, Stites T, Chen Y, Putzki N, Merschhemke M, Gärtner J; PARADIGMS Study Group.

N Engl J Med. 2018 Sep 13;379(11):1017-1027. doi: 10.1056/NEJMoa1800149.

PMID:
30207920
10.

Neuronal microRNA regulation in Experimental Autoimmune Encephalomyelitis.

Juźwik CA, Drake S, Lécuyer MA, Johnson RM, Morquette B, Zhang Y, Charabati M, Sagan SM, Bar-Or A, Prat A, Fournier AE.

Sci Rep. 2018 Sep 7;8(1):13437. doi: 10.1038/s41598-018-31542-y.

11.

MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study.

Fadda G, Brown RA, Longoni G, Castro DA, O'Mahony J, Verhey LH, Branson HM, Waters P, Bar-Or A, Marrie RA, Yeh EA, Narayanan S, Arnold DL, Banwell B; Canadian Pediatric Demyelinating Disease Network.

Lancet Child Adolesc Health. 2018 Mar;2(3):191-204. doi: 10.1016/S2352-4642(18)30026-9. Epub 2018 Feb 1.

PMID:
30169254
12.

Pediatric-onset multiple sclerosis is associated with reduced parental health-related quality of life and family functioning.

O'Mahony J, Marrie RA, Laporte A, Bar-Or A, Yeh EA, Brown A, Dilenge ME, Banwell B; Canadian Pediatric Demyelinating Disease Network.

Mult Scler. 2018 Aug 30:1352458518796676. doi: 10.1177/1352458518796676. [Epub ahead of print]

PMID:
30160208
13.

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.

Cohen JA, Comi G, Arnold DL, Bar-Or A, Selmaj KW, Steinman L, Havrdová EK, Cree BA, Montalbán X, Hartung HP, Huang V, Frohna P, Skolnick BE, Kappos L; RADIANCE Trial Investigators.

Mult Scler. 2018 Jul 25:1352458518789884. doi: 10.1177/1352458518789884. [Epub ahead of print]

PMID:
30043658
14.

Isotype-Switched Autoantibodies Are Necessary To Facilitate Central Nervous System Autoimmune Disease in Aicda-/- and Ung-/- Mice.

Galicia G, Lee DSW, Ramaglia V, Ward LA, Yam JY, Leung LYT, Li R, Handy M, Zhang J, Drohomyrecky PC, Lancaster E, Bar-Or A, Martin A, Gommerman JL.

J Immunol. 2018 Aug 15;201(4):1119-1130. doi: 10.4049/jimmunol.1700729. Epub 2018 Jul 6.

PMID:
29980612
15.

A framework for measurement and harmonization of pediatric multiple sclerosis etiologic research studies: The Pediatric MS Tool-Kit.

Magalhaes S, Banwell B, Bar-Or A, Fortier I, Hanwell HE, Lim M, Matt GE, Neuteboom RF, O'Riordan DL, Schneider PK, Pugliatti M, Shatenstein B, Tansey CM, Wassmer E, Wolfson C.

Mult Scler. 2018 Jun 1:1352458518783345. doi: 10.1177/1352458518783345. [Epub ahead of print]

PMID:
29932341
16.

Reassessing B cell contributions in multiple sclerosis.

Li R, Patterson KR, Bar-Or A.

Nat Immunol. 2018 Jul;19(7):696-707. doi: 10.1038/s41590-018-0135-x. Epub 2018 Jun 20. Review.

PMID:
29925992
17.

Neuroimmune disorders of the central nervous system in children in the molecular era.

Wells E, Hacohen Y, Waldman A, Tillema JM, Soldatos A, Ances B, Benseler S, Bielekova B, Dale RC, Dalmau J, Gaillard W, Gorman M, Greenberg B, Hyslop A, Pardo CA, Tasker RC, Yeh EA, Bar-Or A, Pittock S, Vanderver A, Banwell B; attendees of the International Neuroimmune Meeting.

Nat Rev Neurol. 2018 Jul;14(7):433-445. doi: 10.1038/s41582-018-0024-9. Review. Erratum in: Nat Rev Neurol. 2018 Dec;14(12):749.

PMID:
29925924
18.

Natural Killer Cells Regulate Th17 Cells After Autologous Hematopoietic Stem Cell Transplantation for Relapsing Remitting Multiple Sclerosis.

Darlington PJ, Stopnicki B, Touil T, Doucet JS, Fawaz L, Roberts ME, Boivin MN, Arbour N, Freedman MS, Atkins HL, Bar-Or A.

Front Immunol. 2018 May 7;9:834. doi: 10.3389/fimmu.2018.00834. eCollection 2018.

19.

Detection and clinical correlation of leukocortical lesions in pediatric-onset multiple sclerosis on multi-contrast MRI.

Maranzano J, Till C, Assemlal HE, Fonov V, Brown R, Araujo D, O'Mahony J, Yeh EA, Bar-Or A, Marrie RA, Collins L, Banwell B, Arnold DL, Narayanan S; Canadian Pediatric Demyelinating Disease Network.

Mult Scler. 2018 May 1:1352458518779952. doi: 10.1177/1352458518779952. [Epub ahead of print]

PMID:
29852831
20.

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.

Bar-Or A, Grove RA, Austin DJ, Tolson JM, VanMeter SA, Lewis EW, Derosier FJ, Lopez MC, Kavanagh ST, Miller AE, Sorensen PS.

Neurology. 2018 May 15;90(20):e1805-e1814. doi: 10.1212/WNL.0000000000005516. Epub 2018 Apr 25. Erratum in: Neurology. 2018 Sep 11;91(11):538.

21.

Human central nervous system astrocytes support survival and activation of B cells: implications for MS pathogenesis.

Touil H, Kobert A, Lebeurrier N, Rieger A, Saikali P, Lambert C, Fawaz L, Moore CS, Prat A, Gommerman J, Antel JP, Itoyama Y, Nakashima I, Bar-Or A; Canadian B Cell Team in MS.

J Neuroinflammation. 2018 Apr 19;15(1):114. doi: 10.1186/s12974-018-1136-2.

22.

The Multiple Roles of B Cells in Multiple Sclerosis and Their Implications in Multiple Sclerosis Therapies.

Li R, Bar-Or A.

Cold Spring Harb Perspect Med. 2018 Apr 16. pii: a029108. doi: 10.1101/cshperspect.a029108. [Epub ahead of print]

PMID:
29661809
23.

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.

Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators.

Lancet. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23. Erratum in: Lancet. 2018 Nov 17;392(10160):2170.

PMID:
29576505
24.

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.

Havrdová E, Arnold DL, Bar-Or A, Comi G, Hartung HP, Kappos L, Lublin F, Selmaj K, Traboulsee A, Belachew S, Bennett I, Buffels R, Garren H, Han J, Julian L, Napieralski J, Hauser SL, Giovannoni G.

Mult Scler J Exp Transl Clin. 2018 Mar 12;4(1):2055217318760642. doi: 10.1177/2055217318760642. eCollection 2018 Jan-Mar.

25.

The contribution of secondhand tobacco smoke exposure to pediatric multiple sclerosis risk.

Lavery AM, Collins BN, Waldman AT, Hart CN, Bar-Or A, Marrie RA, Arnold D, O'Mahony J, Banwell B; Canadian Pediatric Demyelinating Disease Network.

Mult Scler. 2018 Jan 1:1352458518757089. doi: 10.1177/1352458518757089. [Epub ahead of print]

PMID:
29393768
26.

MerTK-mediated regulation of myelin phagocytosis by macrophages generated from patients with MS.

Healy LM, Jang JH, Won SY, Lin YH, Touil H, Aljarallah S, Bar-Or A, Antel JP.

Neurol Neuroimmunol Neuroinflamm. 2017 Oct 16;4(6):e402. doi: 10.1212/NXI.0000000000000402. eCollection 2017 Nov.

27.

Cell-based therapeutic strategies for multiple sclerosis.

Scolding NJ, Pasquini M, Reingold SC, Cohen JA; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis.

Brain. 2017 Nov 1;140(11):2776-2796. doi: 10.1093/brain/awx154. Review.

28.

Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis.

Kappos L, Arnold DL, Bar-Or A, Camm AJ, Derfuss T, Sprenger T, Davies M, Piotrowska A, Ni P, Harada T.

Mult Scler. 2018 Oct;24(12):1605-1616. doi: 10.1177/1352458517728343. Epub 2017 Sep 15.

29.

Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod.

Ghadiri M, Fitz-Gerald L, Rezk A, Li R, Nyirenda M, Haegert D, Giacomini PS, Bar-Or A, Antel J.

Mult Scler. 2017 Aug;23(9):1225-1232. doi: 10.1177/1352458517713147.

PMID:
28749311
30.

B cells from patients with multiple sclerosis induce cell death via apoptosis in neurons in vitro.

Lisak RP, Nedelkoska L, Benjamins JA, Schalk D, Bealmear B, Touil H, Li R, Muirhead G, Bar-Or A.

J Neuroimmunol. 2017 Aug 15;309:88-99. doi: 10.1016/j.jneuroim.2017.05.004. Epub 2017 May 17.

PMID:
28601295
31.

Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS.

Fleischer V, Friedrich M, Rezk A, Bühler U, Witsch E, Uphaus T, Bittner S, Groppa S, Tackenberg B, Bar-Or A, Zipp F, Luessi F.

Mult Scler. 2018 Apr;24(5):632-641. doi: 10.1177/1352458517703799. Epub 2017 Apr 24.

PMID:
28436295
32.

Monophasic demyelination reduces brain growth in children.

Aubert-Broche B, Weier K, Longoni G, Fonov VS, Bar-Or A, Marrie RA, Yeh EA, Narayanan S, Arnold DL, Verhey LH, Banwell B, Collins DL; Canadian Pediatric Demyelinating Disease Network.

Neurology. 2017 May 2;88(18):1744-1750. doi: 10.1212/WNL.0000000000003884. Epub 2017 Apr 5.

33.

Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.

Cohen JA, Imrey PB, Planchon SM, Bermel RA, Fisher E, Fox RJ, Bar-Or A, Sharp SL, Skaramagas TT, Jagodnik P, Karafa M, Morrison S, Reese Koc J, Gerson SL, Lazarus HM.

Mult Scler. 2018 Apr;24(4):501-511. doi: 10.1177/1352458517703802. Epub 2017 Apr 6.

PMID:
28381130
34.

Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis.

Ghadiri M, Rezk A, Li R, Evans A, Luessi F, Zipp F, Giacomini PS, Antel J, Bar-Or A.

Neurol Neuroimmunol Neuroinflamm. 2017 Mar 23;4(3):e340. doi: 10.1212/NXI.0000000000000340. eCollection 2017 May.

35.

White matter changes in paediatric multiple sclerosis and monophasic demyelinating disorders.

Longoni G, Brown RA, MomayyezSiahkal P, Elliott C, Narayanan S, Bar-Or A, Marrie RA, Yeh EA, Filippi M, Banwell B, Arnold DL; Canadian Pediatric Demyelinating Disease Network.

Brain. 2017 May 1;140(5):1300-1315. doi: 10.1093/brain/awx041.

PMID:
28334875
36.

Antibody-Independent Function of Human B Cells Contributes to Antifungal T Cell Responses.

Li R, Rezk A, Li H, Gommerman JL, Prat A, Bar-Or A; Canadian B Cells in MS Team.

J Immunol. 2017 Apr 15;198(8):3245-3254. doi: 10.4049/jimmunol.1601572. Epub 2017 Mar 8.

37.

Cyberinfrastructure for Open Science at the Montreal Neurological Institute.

Das S, Glatard T, Rogers C, Saigle J, Paiva S, MacIntyre L, Safi-Harab M, Rousseau ME, Stirling J, Khalili-Mahani N, MacFarlane D, Kostopoulos P, Rioux P, Madjar C, Lecours-Boucher X, Vanamala S, Adalat R, Mohaddes Z, Fonov VS, Milot S, Leppert I, Degroot C, Durcan TM, Campbell T, Moreau J, Dagher A, Collins DL, Karamchandani J, Bar-Or A, Fon EA, Hoge R, Baillet S, Rouleau G, Evans AC.

Front Neuroinform. 2017 Jan 6;10:53. doi: 10.3389/fninf.2016.00053. eCollection 2016.

38.

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21.

39.

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21.

40.

Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis.

Li R, Rezk A, Ghadiri M, Luessi F, Zipp F, Li H, Giacomini PS, Antel J, Bar-Or A.

J Immunol. 2017 Jan 15;198(2):691-698. doi: 10.4049/jimmunol.1601649. Epub 2016 Dec 14.

41.

Evaluating Soluble EMMPRIN as a Marker of Disease Activity in Multiple Sclerosis: Studies of Serum and Cerebrospinal Fluid.

Kaushik DK, Yong HY, Hahn JN, Silva C, Casha S, Hurlbert RJ, Jacques FH, Lisak R, Khan O, Ionete C, Larochelle C, Prat A, Bar-Or A, Yong VW.

PLoS One. 2016 Oct 11;11(10):e0163802. doi: 10.1371/journal.pone.0163802. eCollection 2016.

42.

Restoring immune tolerance in neuromyelitis optica: Part II.

Bar-Or A, Steinman L, Behne JM, Benitez-Ribas D, Chin PS, Clare-Salzler M, Healey D, Kim JI, Kranz DM, Lutterotti A, Martin R, Schippling S, Villoslada P, Wei CH, Weiner HL, Zamvil SS, Smith TJ, Yeaman MR.

Neurol Neuroimmunol Neuroinflamm. 2016 Sep 7;3(5):e277. doi: 10.1212/NXI.0000000000000277. eCollection 2016 Oct. Review.

43.

Restoring immune tolerance in neuromyelitis optica: Part I.

Steinman L, Bar-Or A, Behne JM, Benitez-Ribas D, Chin PS, Clare-Salzler M, Healey D, Kim JI, Kranz DM, Lutterotti A, Martin R, Schippling S, Villoslada P, Wei CH, Weiner HL, Zamvil SS, Yeaman MR, Smith TJ.

Neurol Neuroimmunol Neuroinflamm. 2016 Sep 7;3(5):e276. doi: 10.1212/NXI.0000000000000276. eCollection 2016 Oct. Review.

44.

Immunopathophysiology of pediatric CNS inflammatory demyelinating diseases.

Bar-Or A, Hintzen RQ, Dale RC, Rostasy K, Brück W, Chitnis T.

Neurology. 2016 Aug 30;87(9 Suppl 2):S12-9. doi: 10.1212/WNL.0000000000002821. Review.

PMID:
27572856
45.

Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial.

Kappos L, Arnold DL, Bar-Or A, Camm J, Derfuss T, Kieseier BC, Sprenger T, Greenough K, Ni P, Harada T.

Lancet Neurol. 2016 Oct;15(11):1148-59. doi: 10.1016/S1474-4422(16)30192-2. Epub 2016 Aug 16.

PMID:
27543447
46.

Role of IL-17-producing lymphocytes in severity of multiple sclerosis upon natalizumab treatment.

Bühler U, Fleischer V, Luessi F, Rezk A, Belikan P, Graetz C, Gollan R, Wolf C, Lutz J, Bar-Or A, Siffrin V, Zipp F.

Mult Scler. 2017 Apr;23(4):567-576. doi: 10.1177/1352458516658559. Epub 2016 Jul 21.

PMID:
27436357
47.

Human Mesenchymal Stem Cells Impact Th17 and Th1 Responses Through a Prostaglandin E2 and Myeloid-Dependent Mechanism.

Rozenberg A, Rezk A, Boivin MN, Darlington PJ, Nyirenda M, Li R, Jalili F, Winer R, Artsy EA, Uccelli A, Reese JS, Planchon SM, Cohen JA, Bar-Or A.

Stem Cells Transl Med. 2016 Nov;5(11):1506-1514. doi: 10.5966/sctm.2015-0243. Epub 2016 Jul 11.

48.

Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.

Atkins HL, Bowman M, Allan D, Anstee G, Arnold DL, Bar-Or A, Bence-Bruckler I, Birch P, Bredeson C, Chen J, Fergusson D, Halpenny M, Hamelin L, Huebsch L, Hutton B, Laneuville P, Lapierre Y, Lee H, Martin L, McDiarmid S, O'Connor P, Ramsay T, Sabloff M, Walker L, Freedman MS.

Lancet. 2016 Aug 6;388(10044):576-85. doi: 10.1016/S0140-6736(16)30169-6. Epub 2016 Jun 9.

PMID:
27291994
49.

Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.

Gold R, Arnold DL, Bar-Or A, Hutchinson M, Kappos L, Havrdova E, MacManus DG, Yousry TA, Pozzilli C, Selmaj K, Sweetser MT, Zhang R, Yang M, Potts J, Novas M, Miller DH, Kurukulasuriya NC, Fox RJ, Phillips TJ.

Mult Scler. 2017 Feb;23(2):253-265. doi: 10.1177/1352458516649037. Epub 2016 Jul 11.

50.

Differential transcriptional response profiles in human myeloid cell populations.

Healy LM, Perron G, Won SY, Rao VTS, Guiot MC, Moore C, Bar-Or A, Antel JP.

Clin Immunol. 2018 Apr;189:63-74. doi: 10.1016/j.clim.2016.04.006. Epub 2016 Apr 16.

PMID:
27094466
51.

Central nervous system inflammation across the age span.

Bar-Or A, Antel JP.

Curr Opin Neurol. 2016 Jun;29(3):381-7. doi: 10.1097/WCO.0000000000000331. Review.

PMID:
27035901
52.

Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype.

Gabrusiewicz K, Rodriguez B, Wei J, Hashimoto Y, Healy LM, Maiti SN, Thomas G, Zhou S, Wang Q, Elakkad A, Liebelt BD, Yaghi NK, Ezhilarasan R, Huang N, Weinberg JS, Prabhu SS, Rao G, Sawaya R, Langford LA, Bruner JM, Fuller GN, Bar-Or A, Li W, Colen RR, Curran MA, Bhat KP, Antel JP, Cooper LJ, Sulman EP, Heimberger AB.

JCI Insight. 2016;1(2). pii: e85841. Epub 2016 Feb 25.

53.

MerTK Is a Functional Regulator of Myelin Phagocytosis by Human Myeloid Cells.

Healy LM, Perron G, Won SY, Michell-Robinson MA, Rezk A, Ludwin SK, Moore CS, Hall JA, Bar-Or A, Antel JP.

J Immunol. 2016 Apr 15;196(8):3375-84. doi: 10.4049/jimmunol.1502562. Epub 2016 Mar 9.

54.

Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM.

Giovannoni G, Gold R, Kappos L, Arnold DL, Bar-Or A, Marantz JL, Yang M, Lee A.

Mult Scler J Exp Transl Clin. 2016 Feb 19;2:2055217316634111. doi: 10.1177/2055217316634111. eCollection 2016 Jan-Dec.

55.

Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.

Cohen JA, Arnold DL, Comi G, Bar-Or A, Gujrathi S, Hartung JP, Cravets M, Olson A, Frohna PA, Selmaj KW; RADIANCE Study Group.

Lancet Neurol. 2016 Apr;15(4):373-81. doi: 10.1016/S1474-4422(16)00018-1. Epub 2016 Feb 12.

PMID:
26879276
56.

MicroRNA Expression Patterns in Human Astrocytes in Relation to Anatomical Location and Age.

Rao VT, Ludwin SK, Fuh SC, Sawaya R, Moore CS, Ho MK, Bedell BJ, Sarnat HB, Bar-Or A, Antel JP.

J Neuropathol Exp Neurol. 2016 Feb;75(2):156-66.

PMID:
26802178
57.

Meningeal Tertiary Lymphoid Tissues and Multiple Sclerosis: A Gathering Place for Diverse Types of Immune Cells during CNS Autoimmunity.

Pikor NB, Prat A, Bar-Or A, Gommerman JL.

Front Immunol. 2016 Jan 13;6:657. doi: 10.3389/fimmu.2015.00657. eCollection 2015. Review.

58.

Effects of fumarates on circulating and CNS myeloid cells in multiple sclerosis.

Michell-Robinson MA, Moore CS, Healy LM, Osso LA, Zorko N, Grouza V, Touil H, Poliquin-Lasnier L, Trudelle AM, Giacomini PS, Bar-Or A, Antel JP.

Ann Clin Transl Neurol. 2015 Dec 2;3(1):27-41. doi: 10.1002/acn3.270. eCollection 2016 Jan.

59.

Cytokine-Defined B Cell Responses as Therapeutic Targets in Multiple Sclerosis.

Li R, Rezk A, Healy LM, Muirhead G, Prat A, Gommerman JL, Bar-Or A; MSSRF Canadian B cells in MS Team.

Front Immunol. 2016 Jan 8;6:626. doi: 10.3389/fimmu.2015.00626. eCollection 2015. Review.

60.

B Cells in the Multiple Sclerosis Central Nervous System: Trafficking and Contribution to CNS-Compartmentalized Inflammation.

Michel L, Touil H, Pikor NB, Gommerman JL, Prat A, Bar-Or A.

Front Immunol. 2015 Dec 24;6:636. doi: 10.3389/fimmu.2015.00636. eCollection 2015. Review.

61.

Multiple sclerosis and related disorders: evolving pathophysiologic insights.

Bar-Or A.

Lancet Neurol. 2016 Jan;15(1):9-11. doi: 10.1016/S1474-4422(15)00342-7. Epub 2015 Dec 8. Review. No abstract available.

PMID:
26700897
62.

Cytokine-producing B cells: a translational view on their roles in human and mouse autoimmune diseases.

Lino AC, Dörner T, Bar-Or A, Fillatreau S.

Immunol Rev. 2016 Jan;269(1):130-44. doi: 10.1111/imr.12374. Review.

PMID:
26683150
63.

Integration of Th17- and Lymphotoxin-Derived Signals Initiates Meningeal-Resident Stromal Cell Remodeling to Propagate Neuroinflammation.

Pikor NB, Astarita JL, Summers-Deluca L, Galicia G, Qu J, Ward LA, Armstrong S, Dominguez CX, Malhotra D, Heiden B, Kay R, Castanov V, Touil H, Boon L, O'Connor P, Bar-Or A, Prat A, Ramaglia V, Ludwin S, Turley SJ, Gommerman JL.

Immunity. 2015 Dec 15;43(6):1160-73. doi: 10.1016/j.immuni.2015.11.010.

64.

Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience.

Gold R, Phillips JT, Havrdova E, Bar-Or A, Kappos L, Kim N, Thullen T, Valencia P, Oliva L, Novas M, Li J, Sweetser MT, Kurukulasuriya N, Viglietta V, Fox RJ.

Neurol Ther. 2015 Dec;4(2):93-104. doi: 10.1007/s40120-015-0033-1. Epub 2015 Oct 12.

65.

Transcription factor Nr4a1 couples sympathetic and inflammatory cues in CNS-recruited macrophages to limit neuroinflammation.

Shaked I, Hanna RN, Shaked H, Chodaczek G, Nowyhed HN, Tweet G, Tacke R, Basat AB, Mikulski Z, Togher S, Miller J, Blatchley A, Salek-Ardakani S, Darvas M, Kaikkonen MU, Thomas GD, Lai-Wing-Sun S, Rezk A, Bar-Or A, Glass CK, Bandukwala H, Hedrick CC.

Nat Immunol. 2015 Dec;16(12):1228-34. doi: 10.1038/ni.3321. Epub 2015 Nov 2.

66.

Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy.

Li R, Rezk A, Miyazaki Y, Hilgenberg E, Touil H, Shen P, Moore CS, Michel L, Althekair F, Rajasekharan S, Gommerman JL, Prat A, Fillatreau S, Bar-Or A; Canadian B cells in MS Team.

Sci Transl Med. 2015 Oct 21;7(310):310ra166. doi: 10.1126/scitranslmed.aab4176.

PMID:
26491076
67.

Sequencing the immunopathologic heterogeneity in multiple sclerosis.

Antel JP, Ludwin SK, Bar-Or A.

Ann Clin Transl Neurol. 2015 Sep;2(9):873-4. doi: 10.1002/acn3.230. No abstract available.

68.

Neuroinflammation: Ways in Which the Immune System Affects the Brain.

Ransohoff RM, Schafer D, Vincent A, Blachère NE, Bar-Or A.

Neurotherapeutics. 2015 Oct;12(4):896-909. doi: 10.1007/s13311-015-0385-3. Review.

69.

Update on biomarkers in neuromyelitis optica.

Melamed E, Levy M, Waters PJ, Sato DK, Bennett JL, John GR, Hooper DC, Saiz A, Bar-Or A, Kim HJ, Pandit L, Leite MI, Asgari N, Kissani N, Hintzen R, Marignier R, Jarius S, Marcelletti J, Smith TJ, Yeaman MR, Han MH, Aktas O, Apiwattanakul M, Banwell B, Bichuetti D, Broadley S, Cabre P, Chitnis T, De Seze J, Fujihara K, Greenberg B, Hellwig K, Iorio R, Jarius S, Klawiter E, Kleiter I, Lana-Peixoto M, Nakashima, O'Connor K, Palace J, Paul F, Prayoonwiwat N, Ruprecht K, Stuve O, Tedder T, Tenembaum S, Garrahan JP, Aires B, van Herle K, van Pelt D, Villoslada P, Waubant E, Weinshenker B, Wingerchuk D, Würfel J, Zamvil S.

Neurol Neuroimmunol Neuroinflamm. 2015 Jul 23;2(4):e134. doi: 10.1212/NXI.0000000000000134. eCollection 2015 Aug. Review.

70.

Viral exposures and MS outcome in a prospective cohort of children with acquired demyelination.

Makhani N, Banwell B, Tellier R, Yea C, McGovern S, O'Mahony J, Ahorro JM, Arnold D, Sadovnick AD, Marrie RA, Bar-Or A; Canadian Pediatric Demyelinating Disease Network.

Mult Scler. 2016 Mar;22(3):385-8. doi: 10.1177/1352458515595876. Epub 2015 Jul 21.

PMID:
26199356
71.

Recovery From Central Nervous System Acute Demyelination in Children.

O'Mahony J, Marrie RA, Laporte A, Yeh EA, Bar-Or A, Phan C, Buckley D, Callen D, Connolly MB, Pohl D, Dilenge ME, Bernard G, Lortie A, Lowry N, MacDonald EA, Meek D, Sébire G, Venkateswaran S, Wood E, Yager J, Banwell B.

Pediatrics. 2015 Jul;136(1):e115-23. doi: 10.1542/peds.2015-0028. Epub 2015 Jun 1.

72.

TLR2 stimulation regulates the balance between regulatory T cell and Th17 function: a novel mechanism of reduced regulatory T cell function in multiple sclerosis.

Nyirenda MH, Morandi E, Vinkemeier U, Constantin-Teodosiu D, Drinkwater S, Mee M, King L, Podda G, Zhang GX, Ghaemmaghami A, Constantinescu CS, Bar-Or A, Gran B.

J Immunol. 2015 Jun 15;194(12):5761-74. doi: 10.4049/jimmunol.1400472. Epub 2015 May 15.

73.

B lymphocytes in neuromyelitis optica.

Bennett JL, O'Connor KC, Bar-Or A, Zamvil SS, Hemmer B, Tedder TF, von Büdingen HC, Stuve O, Yeaman MR, Smith TJ, Stadelmann C.

Neurol Neuroimmunol Neuroinflamm. 2015 May 7;2(3):e104. doi: 10.1212/NXI.0000000000000104. eCollection 2015 Jun. Review.

74.

High false-positive rate of questionnaire-based restless legs syndrome diagnosis in multiple sclerosis.

Mery V, Kimoff RJ, Suarez I, Benedetti A, Kaminska M, Robinson A, Lapierre Y, Bar-Or A, Trojan DA.

Sleep Med. 2015 Jul;16(7):877-82. doi: 10.1016/j.sleep.2015.02.529. Epub 2015 Mar 6.

PMID:
25912601
75.

Roles of microglia in brain development, tissue maintenance and repair.

Michell-Robinson MA, Touil H, Healy LM, Owen DR, Durafourt BA, Bar-Or A, Antel JP, Moore CS.

Brain. 2015 May;138(Pt 5):1138-59. doi: 10.1093/brain/awv066. Epub 2015 Mar 29. Review.

76.

P2Y12 expression and function in alternatively activated human microglia.

Moore CS, Ase AR, Kinsara A, Rao VT, Michell-Robinson M, Leong SY, Butovsky O, Ludwin SK, Séguéla P, Bar-Or A, Antel JP.

Neurol Neuroimmunol Neuroinflamm. 2015 Mar 19;2(2):e80. doi: 10.1212/NXI.0000000000000080. eCollection 2015 Apr. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2015 Jun;2(3):e106.

77.

Coexpression of TIGIT and FCRL3 identifies Helios+ human memory regulatory T cells.

Bin Dhuban K, d'Hennezel E, Nashi E, Bar-Or A, Rieder S, Shevach EM, Nagata S, Piccirillo CA.

J Immunol. 2015 Apr 15;194(8):3687-96. doi: 10.4049/jimmunol.1401803. Epub 2015 Mar 11.

78.

Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials.

Viglietta V, Miller D, Bar-Or A, Phillips JT, Arnold DL, Selmaj K, Kita M, Hutchinson M, Yang M, Zhang R, Dawson KT, Sheikh SI, Fox RJ, Gold R.

Ann Clin Transl Neurol. 2015 Feb;2(2):103-18. doi: 10.1002/acn3.148. Epub 2014 Dec 4.

79.

Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens.

Bar-Or A, Wiendl H, Miller B, Benamor M, Truffinet P, Church M, Menguy-Vacheron F.

Neurol Neuroimmunol Neuroinflamm. 2015 Feb 12;2(2):e70. doi: 10.1212/NXI.0000000000000070. eCollection 2015 Apr.

80.

Humor in systemic lupus erythematosus.

Moura CS, Li R, Lawrie S, Bar-Or A, Clarke AE, Da Costa D, Banerjee D, Bernatsky S, Lee JL, Pineau CA.

Eur J Rheumatol. 2015 Mar;2(1):5-9. Epub 2015 Mar 1.

81.

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study.

Miller DH, Fox RJ, Phillips JT, Hutchinson M, Havrdova E, Kita M, Wheeler-Kingshott CA, Tozer DJ, MacManus DG, Yousry TA, Goodsell M, Yang M, Zhang R, Viglietta V, Dawson KT; CONFIRM study investigators.

Neurology. 2015 Mar 17;84(11):1145-52. doi: 10.1212/WNL.0000000000001360. Epub 2015 Feb 13.

82.

High CCR5 expression in natalizumab-associated progressive multifocal leukoencephalopathy immune reconstitution inflammatory syndrome supports treatment with the CCR5 inhibitor maraviroc.

Stork L, Brück W, Bar-Or A, Metz I.

Acta Neuropathol. 2015 Mar;129(3):467-8. doi: 10.1007/s00401-015-1391-6. Epub 2015 Jan 22. No abstract available.

PMID:
25604548
83.

Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab.

Villar LM, Costa-Frossard L, Masterman T, Fernandez O, Montalban X, Casanova B, Izquierdo G, Coret F, Tumani H, Saiz A, Arroyo R, Fink K, Leyva L, Espejo C, Simó-Castelló M, García-Sánchez MI, Lauda F, Llufriú S, Álvarez-Lafuente R, Olascoaga J, Prada A, Oterino A, de Andrés C, Tintoré M, Ramió-Torrentà L, Rodríguez-Martín E, Picón C, Comabella M, Quintana E, Agüera E, Díaz S, Fernandez-Bolaños R, García-Merino JA, Landete L, Menéndez-González M, Navarro L, Pérez D, Sánchez-López F, Serrano-Castro PJ, Tuñón A, Espiño M, Muriel A, Bar-Or A, Álvarez-Cermeño JC.

Ann Neurol. 2015 Mar;77(3):447-57. doi: 10.1002/ana.24345. Epub 2015 Jan 30.

PMID:
25581547
84.

Effects of blood transportation on human peripheral mononuclear cell yield, phenotype and function: implications for immune cell biobanking.

Posevitz-Fejfár A, Posevitz V, Gross CC, Bhatia U, Kurth F, Schütte V, Bar-Or A, Meuth SG, Wiendl H.

PLoS One. 2014 Dec 26;9(12):e115920. doi: 10.1371/journal.pone.0115920. eCollection 2014.

85.

Puberty in females enhances the risk of an outcome of multiple sclerosis in children and the development of central nervous system autoimmunity in mice.

Ahn JJ, O'Mahony J, Moshkova M, Hanwell HE, Singh H, Zhang MA, Marrie RA, Bar-Or A, Sadovnick DA, Dunn SE, Banwell BL.

Mult Scler. 2015 May;21(6):735-48. doi: 10.1177/1352458514551453. Epub 2014 Dec 22.

PMID:
25533291
86.

Direct and indirect effects of immune and central nervous system-resident cells on human oligodendrocyte progenitor cell differentiation.

Moore CS, Cui QL, Warsi NM, Durafourt BA, Zorko N, Owen DR, Antel JP, Bar-Or A.

J Immunol. 2015 Jan 15;194(2):761-72. doi: 10.4049/jimmunol.1401156. Epub 2014 Dec 10.

87.

Epitope spreading as an early pathogenic event in pediatric multiple sclerosis.

Quintana FJ, Patel B, Yeste A, Nyirenda M, Kenison J, Rahbari R, Fetco D, Hussain M, O'Mahony J, Magalhaes S, McGowan M, Johnson T, Rajasekharan S, Narayanan S, Arnold DL, Weiner HL, Banwell B, Bar-Or A; Canadian Pediatric Demyelinating Disease Network.

Neurology. 2014 Dec 9;83(24):2219-26. doi: 10.1212/WNL.0000000000001066. Epub 2014 Nov 7.

88.

Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study.

Arnold DL, Gold R, Kappos L, Bar-Or A, Giovannoni G, Selmaj K, Yang M, Zhang R, Stephan M, Sheikh SI, Dawson KT.

J Neurol. 2014 Dec;261(12):2429-37. doi: 10.1007/s00415-014-7504-7. Epub 2014 Oct 1.

89.

Rasmussen encephalitis and comorbid autoimmune diseases: A window into disease mechanism?

Amrom D, Kinay D, Hart Y, Berkovic SF, Laxer K, Andermann F, Andermann E, Bar-Or A.

Neurology. 2014 Sep 16;83(12):1049-55. doi: 10.1212/WNL.0000000000000791. Epub 2014 Aug 20.

90.

Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research.

Waldman A, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M, Banwell B.

Lancet Neurol. 2014 Sep;13(9):936-48. doi: 10.1016/S1474-4422(14)70093-6. Review.

91.

A novel microRNA-132-sirtuin-1 axis underlies aberrant B-cell cytokine regulation in patients with relapsing-remitting multiple sclerosis [corrected].

Miyazaki Y, Li R, Rezk A, Misirliyan H, Moore C, Farooqi N, Solis M, Goiry LG, de Faria Junior O, Dang VD, Colman D, Dhaunchak AS, Antel J, Gommerman J, Prat A, Fillatreau S, Bar-Or A; CIHR/MSSC New Emerging Team Grant in Clinical Autoimmunity; MSSRF Canadian B cells in MS Team.

PLoS One. 2014 Aug 19;9(8):e105421. doi: 10.1371/journal.pone.0105421. eCollection 2014. Erratum in: PLoS One. 2014;9(9):e109041.

92.

Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study.

Arnold DL, Gold R, Kappos L, Bar-Or A, Giovannoni G, Selmaj K, Yang M, Zhang R, Stephan M, Sheikh SI, Dawson KT.

J Neurol. 2014 Sep;261(9):1794-802. doi: 10.1007/s00415-014-7412-x. Epub 2014 Jul 3.

93.

Teriflunomide (Aubagio®) for the treatment of multiple sclerosis.

Bar-Or A.

Exp Neurol. 2014 Dec;262 Pt A:57-65. doi: 10.1016/j.expneurol.2014.06.005. Epub 2014 Jun 10.

PMID:
24925677
94.

Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis.

Villar LM, Casanova B, Ouamara N, Comabella M, Jalili F, Leppert D, de Andrés C, Izquierdo G, Arroyo R, Avşar T, Lapin SV, Johnson T, Montalbán X, Fernández O, Álvarez-Lafuente R, Masterman D, García-Sánchez MI, Coret F, Siva A, Evdoshenko E, Álvarez-Cermeño JC, Bar-Or A.

Ann Neurol. 2014 Aug;76(2):231-40. doi: 10.1002/ana.24190. Epub 2014 Jul 2.

PMID:
24909126
95.

Teriflunomide and its mechanism of action in multiple sclerosis.

Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H.

Drugs. 2014 Apr;74(6):659-74. doi: 10.1007/s40265-014-0212-x. Review.

96.

IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases.

Shen P, Roch T, Lampropoulou V, O'Connor RA, Stervbo U, Hilgenberg E, Ries S, Dang VD, Jaimes Y, Daridon C, Li R, Jouneau L, Boudinot P, Wilantri S, Sakwa I, Miyazaki Y, Leech MD, McPherson RC, Wirtz S, Neurath M, Hoehlig K, Meinl E, Grützkau A, Grün JR, Horn K, Kühl AA, Dörner T, Bar-Or A, Kaufmann SHE, Anderton SM, Fillatreau S.

Nature. 2014 Mar 20;507(7492):366-370. doi: 10.1038/nature12979. Epub 2014 Feb 23.

97.

Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis.

Sato DK, Nakashima I, Bar-Or A, Misu T, Suzuki C, Nishiyama S, Kuroda H, Fujihara K, Aoki M.

J Neuroimmunol. 2014 Mar 15;268(1-2):95-8. doi: 10.1016/j.jneuroim.2014.01.008. Epub 2014 Jan 23.

PMID:
24507619
98.

Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome.

Giacomini PS, Rozenberg A, Metz I, Araujo D, Arbour N, Bar-Or A; Maraviroc in Multiple Sclerosis–Associated PML–IRIS (MIMSAPI) Group.

N Engl J Med. 2014 Jan 30;370(5):486-8. doi: 10.1056/NEJMc1304828. No abstract available.

99.

Naive CD4 T-cell activation identifies MS patients having rapid transition to progressive MS.

Zastepa E, Fitz-Gerald L, Hallett M, Antel J, Bar-Or A, Baranzini S, Lapierre Y, Haegert DG.

Neurology. 2014 Feb 25;82(8):681-90. doi: 10.1212/WNL.0000000000000146. Epub 2014 Jan 22. Erratum in: Neurology. 2014 Apr 1;82(13):1193.

100.

Risk genes associated with pediatric-onset MS but not with monophasic acquired CNS demyelination.

van Pelt ED, Mescheriakova JY, Makhani N, Ketelslegers IA, Neuteboom RF, Kundu S, Broer L, Janssens C, Catsman-Berrevoets CE, van Duijn CM, Banwell B, Bar-Or A, Hintzen RQ.

Neurology. 2013 Dec 3;81(23):1996-2001. doi: 10.1212/01.wnl.0000436934.40034eb. Epub 2013 Nov 6.

PMID:
24198294
101.

Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study.

Kappos L, Gold R, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Sarda SP, Agarwal S, Zhang A, Sheikh SI, Seidman E, Dawson KT.

Mult Scler. 2014 Feb;20(2):243-52. doi: 10.1177/1352458513507817. Epub 2013 Oct 22.

PMID:
24150779
102.

Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis.

Henault D, Galleguillos L, Moore C, Johnson T, Bar-Or A, Antel J.

Neurology. 2013 Nov 12;81(20):1768-72. doi: 10.1212/01.wnl.0000435564.92609.2c. Epub 2013 Oct 16.

103.

Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone.

Evdoshenko E, Maslyanskiy A, Lapin S, Zaslavsky L, Dobson R, Totolian A, Skoromets A, Bar-Or A.

ISRN Neurol. 2013 Sep 10;2013:748127. doi: 10.1155/2013/748127. eCollection 2013.

104.

Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases.

Mayer MC, Breithaupt C, Reindl M, Schanda K, Rostásy K, Berger T, Dale RC, Brilot F, Olsson T, Jenne D, Pröbstel AK, Dornmair K, Wekerle H, Hohlfeld R, Banwell B, Bar-Or A, Meinl E.

J Immunol. 2013 Oct 1;191(7):3594-604. doi: 10.4049/jimmunol.1301296. Epub 2013 Sep 6.

105.

Epstein-Barr virus in oral shedding of children with multiple sclerosis.

Yea C, Tellier R, Chong P, Westmacott G, Marrie RA, Bar-Or A, Banwell B; Canadian Pediatric Demyelinating Disease Network.

Neurology. 2013 Oct 15;81(16):1392-9. doi: 10.1212/WNL.0b013e3182a841e4. Epub 2013 Sep 6.

106.

Considering a career in neurology research? Heed these words.

Jensen FE, Paulson HL, Bar-Or A.

Ann Neurol. 2013 Sep;74(3):A12. doi: 10.1002/ana.24008. No abstract available.

PMID:
25813981
107.

Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials.

Verhey LH, Signori A, Arnold DL, Bar-Or A, Sadovnick AD, Marrie RA, Banwell B, Sormani MP.

Neurology. 2013 Oct 1;81(14):1215-21. doi: 10.1212/WNL.0b013e3182a6cb9b. Epub 2013 Aug 21.

108.

Premature immune senescence in children with MS: Too young to go steady.

Bar-Or A, Muraro PA.

Neurology. 2013 Aug 27;81(9):778-9. doi: 10.1212/WNL.0b013e3182a2dd3f. Epub 2013 Aug 2. No abstract available.

PMID:
23911757
109.

A further TWEAK to multiple sclerosis pathophysiology.

Nazeri A, Heydarpour P, Sadaghiani S, Sahraian MA, Burkly LC, Bar-Or A.

Mol Neurobiol. 2014 Feb;49(1):78-87. doi: 10.1007/s12035-013-8490-y. Epub 2013 Jul 20. Review.

PMID:
23873135
110.

Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis.

Bar-Or A, Freedman MS, Kremenchutzky M, Menguy-Vacheron F, Bauer D, Jodl S, Truffinet P, Benamor M, Chambers S, O'Connor PW.

Neurology. 2013 Aug 6;81(6):552-8. doi: 10.1212/WNL.0b013e31829e6fbf. Epub 2013 Jul 12.

111.

miR-155 as a multiple sclerosis-relevant regulator of myeloid cell polarization.

Moore CS, Rao VT, Durafourt BA, Bedell BJ, Ludwin SK, Bar-Or A, Antel JP.

Ann Neurol. 2013 Nov;74(5):709-20. doi: 10.1002/ana.23967. Epub 2013 Sep 23.

PMID:
23818336
112.

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study.

Bar-Or A, Gold R, Kappos L, Arnold DL, Giovannoni G, Selmaj K, O'Gorman J, Stephan M, Dawson KT.

J Neurol. 2013 Sep;260(9):2297-305.

PMID:
23797999
113.

Serum autoantibodies to myelin peptides distinguish acute disseminated encephalomyelitis from relapsing-remitting multiple sclerosis.

Van Haren K, Tomooka BH, Kidd BA, Banwell B, Bar-Or A, Chitnis T, Tenembaum SN, Pohl D, Rostasy K, Dale RC, O'Connor KC, Hafler DA, Steinman L, Robinson WH.

Mult Scler. 2013 Nov;19(13):1726-33. doi: 10.1177/1352458513485653. Epub 2013 Apr 23.

114.

Dual effects of daily FTY720 on human astrocytes in vitro: relevance for neuroinflammation.

Wu C, Leong SY, Moore CS, Cui QL, Gris P, Bernier LP, Johnson TA, Séguéla P, Kennedy TE, Bar-Or A, Antel JP.

J Neuroinflammation. 2013 Mar 19;10:41. doi: 10.1186/1742-2094-10-41.

115.

International Pediatric MS Study Group Clinical Trials Summit: meeting report.

Chitnis T, Tardieu M, Amato MP, Banwell B, Bar-Or A, Ghezzi A, Kornberg A, Krupp LB, Pohl D, Rostasy K, Tenembaum S, Waubant E, Wassmer E.

Neurology. 2013 Mar 19;80(12):1161-8. doi: 10.1212/WNL.0b013e318288694e.

116.

Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation.

Darlington PJ, Touil T, Doucet JS, Gaucher D, Zeidan J, Gauchat D, Corsini R, Kim HJ, Duddy M, Jalili F, Arbour N, Kebir H, Chen J, Arnold DL, Bowman M, Antel J, Prat A, Freedman MS, Atkins H, Sekaly R, Cheynier R, Bar-Or A; Canadian MS/BMT Study Group.

Ann Neurol. 2013 Mar;73(3):341-54. doi: 10.1002/ana.23784. Epub 2013 Mar 5.

PMID:
23463494
117.

Epidural blood patch in a patient with multiple sclerosis: is it safe?

Koeva V, Bar-Or A, Gendron D, Backman SB.

Can J Anaesth. 2013 May;60(5):479-83. doi: 10.1007/s12630-013-9904-z. Epub 2013 Mar 2.

PMID:
23456228
118.

MicroRNA dysregulation in multiple sclerosis.

de Faria O Jr, Moore CS, Kennedy TE, Antel JP, Bar-Or A, Dhaunchak AS.

Front Genet. 2013 Jan 22;3:311. doi: 10.3389/fgene.2012.00311. eCollection 2012. Erratum in: Front Genet. 2013;4:90.

119.

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.

Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT; DEFINE Study Investigators.

N Engl J Med. 2012 Sep 20;367(12):1098-107. Erratum in: N Engl J Med. 2012 Dec 13;367(24):2362.

120.

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT; CONFIRM Study Investigators.

N Engl J Med. 2012 Sep 20;367(12):1087-97. Erratum in: N Engl J Med. 2012 Oct 25;367(17):1673.

121.

2010 McDonald criteria for diagnosing pediatric multiple sclerosis.

Sadaka Y, Verhey LH, Shroff MM, Branson HM, Arnold DL, Narayanan S, Sled JG, Bar-Or A, Sadovnick AD, McGowan M, Marrie RA, Banwell B; Canadian Pediatric Demyelinating Disease Network.

Ann Neurol. 2012 Aug;72(2):211-23. doi: 10.1002/ana.23575.

PMID:
22926854
122.

A condensed performance-validation strategy for multiplex detection kits used in studies of human clinical samples.

Belabani C, Rajasekharan S, Poupon V, Johnson T, Bar-Or A; CIHR/MSSC NET in Clinical Autoimmunity; Canadian Pediatric Demyelinating Disease Network.

J Immunol Methods. 2013 Jan 31;387(1-2):1-10. doi: 10.1016/j.jim.2012.08.002. Epub 2012 Aug 11.

PMID:
22917931
123.

Impact of sleep disorder treatment on fatigue in multiple sclerosis.

Côté I, Trojan DA, Kaminska M, Cardoso M, Benedetti A, Weiss D, Robinson A, Bar-Or A, Lapierre Y, Kimoff RJ.

Mult Scler. 2013 Apr;19(4):480-9. doi: 10.1177/1352458512455958. Epub 2012 Aug 22.

PMID:
22914848
124.

Autoantibodies against aquaporin-4 and myelin oligodendrocyte glycoprotein in paediatric CNS demyelination: Recent developments and future directions.

Dale RC, Banwell B, Bar-Or A, Brilot F.

Mult Scler Relat Disord. 2012 Jul;1(3):116-22. doi: 10.1016/j.msard.2012.03.003. Epub 2012 Mar 31. Review.

PMID:
25877076
125.

Masquerades of acquired demyelination in children: experiences of a national demyelinating disease program.

O'Mahony J, Bar-Or A, Arnold DL, Sadovnick AD, Marrie RA, Banwell B; Canadian Pediatric Demyelinating Disease Network.

J Child Neurol. 2013 Feb;28(2):184-97. doi: 10.1177/0883073812443006. Epub 2012 May 9.

PMID:
22573735
126.

B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells.

Barr TA, Shen P, Brown S, Lampropoulou V, Roch T, Lawrie S, Fan B, O'Connor RA, Anderton SM, Bar-Or A, Fillatreau S, Gray D.

J Exp Med. 2012 May 7;209(5):1001-10. doi: 10.1084/jem.20111675. Epub 2012 Apr 30.

127.

Implication of perturbed axoglial apparatus in early pediatric multiple sclerosis.

Dhaunchak AS, Becker C, Schulman H, De Faria O Jr, Rajasekharan S, Banwell B, Colman DR, Bar-Or A; Canadian Pediatric Demyelinating Disease Group.

Ann Neurol. 2012 May;71(5):601-13. doi: 10.1002/ana.22693. Epub 2012 Apr 4.

PMID:
22473675
128.

Regulation of miRNA 219 and miRNA Clusters 338 and 17-92 in Oligodendrocytes.

de Faria O Jr, Cui QL, Bin JM, Bull SJ, Kennedy TE, Bar-Or A, Antel JP, Colman DR, Dhaunchak AS.

Front Genet. 2012 Mar 28;3:46. doi: 10.3389/fgene.2012.00046. eCollection 2012.

129.

Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study.

Waubant E, Pelletier D, Mass M, Cohen JA, Kita M, Cross A, Bar-Or A, Vollmer T, Racke M, Stüve O, Schwid S, Goodman A, Kachuck N, Preiningerova J, Weinstock-Guttman B, Calabresi PA, Miller A, Mokhtarani M, Iklé D, Murphy S, Kopetskie H, Ding L, Rosenberg E, Spencer C, Zamvil SS; ITN STAyCIS Study Group; ITN020AI Study Management Team.

Neurology. 2012 Apr 10;78(15):1171-8. doi: 10.1212/WNL.0b013e31824f7fdd. Epub 2012 Mar 28.

130.

Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro.

Lisak RP, Benjamins JA, Nedelkoska L, Barger JL, Ragheb S, Fan B, Ouamara N, Johnson TA, Rajasekharan S, Bar-Or A.

J Neuroimmunol. 2012 May 15;246(1-2):85-95. doi: 10.1016/j.jneuroim.2012.02.015. Epub 2012 Mar 28.

PMID:
22458983
131.

From bench to MS bedside: challenges translating biomarker discovery to clinical practice.

Rajasekharan S, Bar-Or A; CIHR/MSSC NET in Clinical Autoimmunity.

J Neuroimmunol. 2012 Jul 15;248(1-2):66-72. doi: 10.1016/j.jneuroim.2012.01.006. Epub 2012 Feb 29. Review.

PMID:
22381245
132.

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years.

Confavreux C, Li DK, Freedman MS, Truffinet P, Benzerdjeb H, Wang D, Bar-Or A, Traboulsee AL, Reiman LE, O'Connor PW; Teriflunomide Multiple Sclerosis Trial Group.

Mult Scler. 2012 Sep;18(9):1278-89. Epub 2012 Feb 3.

133.

Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays.

Waters PJ, McKeon A, Leite MI, Rajasekharan S, Lennon VA, Villalobos A, Palace J, Mandrekar JN, Vincent A, Bar-Or A, Pittock SJ.

Neurology. 2012 Feb 28;78(9):665-71; discussion 669. doi: 10.1212/WNL.0b013e318248dec1. Epub 2012 Feb 1.

134.

Comparison of polarization properties of human adult microglia and blood-derived macrophages.

Durafourt BA, Moore CS, Zammit DA, Johnson TA, Zaguia F, Guiot MC, Bar-Or A, Antel JP.

Glia. 2012 May;60(5):717-27. doi: 10.1002/glia.22298. Epub 2012 Jan 30.

PMID:
22290798
135.

Polysomnographic measures of disturbed sleep are associated with reduced quality of life in multiple sclerosis.

Trojan DA, Kaminska M, Bar-Or A, Benedetti A, Lapierre Y, Da Costa D, Robinson A, Cardoso M, Schwartzman K, Kimoff RJ.

J Neurol Sci. 2012 May 15;316(1-2):158-63. doi: 10.1016/j.jns.2011.12.013. Epub 2012 Jan 16.

PMID:
22251932
136.

Obstructive sleep apnea is associated with fatigue in multiple sclerosis.

Kaminska M, Kimoff RJ, Benedetti A, Robinson A, Bar-Or A, Lapierre Y, Schwartzman K, Trojan DA.

Mult Scler. 2012 Aug;18(8):1159-69. doi: 10.1177/1352458511432328. Epub 2011 Dec 19.

PMID:
22183937
137.

Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis.

Chitnis T, Tenembaum S, Banwell B, Krupp L, Pohl D, Rostasy K, Yeh EA, Bykova O, Wassmer E, Tardieu M, Kornberg A, Ghezzi A; International Pediatric Multiple Sclerosis Study Group.

Mult Scler. 2012 Jan;18(1):116-27. doi: 10.1177/1352458511430704. Epub 2011 Dec 6.

PMID:
22146610
138.

IL-17A and IL-17F expression in B lymphocytes.

Vazquez-Tello A, Halwani R, Li R, Nadigel J, Bar-Or A, Mazer BD, Eidelman DH, Al-Muhsen S, Hamid Q.

Int Arch Allergy Immunol. 2012;157(4):406-16. doi: 10.1159/000329527. Epub 2011 Nov 25.

139.

MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study.

Verhey LH, Branson HM, Shroff MM, Callen DJ, Sled JG, Narayanan S, Sadovnick AD, Bar-Or A, Arnold DL, Marrie RA, Banwell B; Canadian Pediatric Demyelinating Disease Network.

Lancet Neurol. 2011 Dec;10(12):1065-73. doi: 10.1016/S1474-4422(11)70250-2. Epub 2011 Nov 6.

PMID:
22067635
140.

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.

Kappos L, Li D, Calabresi PA, O'Connor P, Bar-Or A, Barkhof F, Yin M, Leppert D, Glanzman R, Tinbergen J, Hauser SL.

Lancet. 2011 Nov 19;378(9805):1779-87. doi: 10.1016/S0140-6736(11)61649-8. Epub 2011 Oct 31.

PMID:
22047971
141.

B cells in multiple sclerosis: connecting the dots.

von Büdingen HC, Bar-Or A, Zamvil SS.

Curr Opin Immunol. 2011 Dec;23(6):713-20. doi: 10.1016/j.coi.2011.09.003. Epub 2011 Oct 7. Review.

142.

A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS.

Freedman MS, Bar-Or A, Oger J, Traboulsee A, Patry D, Young C, Olsson T, Li D, Hartung HP, Krantz M, Ferenczi L, Verco T; MAESTRO-01 Investigators.

Neurology. 2011 Oct 18;77(16):1551-60. doi: 10.1212/WNL.0b013e318233b240. Epub 2011 Oct 5.

PMID:
21975206
143.

Neurite outgrowth is differentially impacted by distinct immune cell subsets.

Pool M, Rambaldi I, Darlington PJ, Wright MC, Fournier AE, Bar-Or A.

Mol Cell Neurosci. 2012 Jan;49(1):68-76. doi: 10.1016/j.mcn.2011.09.004. Epub 2011 Sep 22.

PMID:
21971580
144.

Targeting progressive neuroaxonal injury: lessons from multiple sclerosis.

Bar-Or A, Rieckmann P, Traboulsee A, Yong VW.

CNS Drugs. 2011 Sep 1;25(9):783-99. doi: 10.2165/11587820-000000000-00000. Review.

PMID:
21870889
145.

Harnessing the therapeutic potential of mesenchymal stem cells in multiple sclerosis.

Darlington PJ, Boivin MN, Bar-Or A.

Expert Rev Neurother. 2011 Sep;11(9):1295-303. doi: 10.1586/ern.11.113. Review.

146.

Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis.

Pröbstel AK, Dornmair K, Bittner R, Sperl P, Jenne D, Magalhaes S, Villalobos A, Breithaupt C, Weissert R, Jacob U, Krumbholz M, Kuempfel T, Blaschek A, Stark W, Gärtner J, Pohl D, Rostasy K, Weber F, Forne I, Khademi M, Olsson T, Brilot F, Tantsis E, Dale RC, Wekerle H, Hohlfeld R, Banwell B, Bar-Or A, Meinl E, Derfuss T.

Neurology. 2011 Aug 9;77(6):580-8. doi: 10.1212/WNL.0b013e318228c0b1. Epub 2011 Jul 27.

PMID:
21795651
147.

TLR2 stimulation drives human naive and effector regulatory T cells into a Th17-like phenotype with reduced suppressive function.

Nyirenda MH, Sanvito L, Darlington PJ, O'Brien K, Zhang GX, Constantinescu CS, Bar-Or A, Gran B.

J Immunol. 2011 Sep 1;187(5):2278-90. doi: 10.4049/jimmunol.1003715. Epub 2011 Jul 20.

148.

Myeloid lineage cells inhibit neurite outgrowth through a myosin II-dependent mechanism.

Pool M, Rambaldi I, Durafourt BA, Wright MC, Antel JP, Bar-Or A, Fournier AE.

J Neuroimmunol. 2011 Aug 15;237(1-2):101-5. doi: 10.1016/j.jneuroim.2011.06.004. Epub 2011 Jul 7.

PMID:
21737147
149.

Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis.

Kimball S, Vieth R, Dosch HM, Bar-Or A, Cheung R, Gagne D, O'Connor P, D'Souza C, Ursell M, Burton JM.

J Clin Endocrinol Metab. 2011 Sep;96(9):2826-34. doi: 10.1210/jc.2011-0325. Epub 2011 Jun 22.

150.

Reduction of the peripheral blood CD56(bright) NK lymphocyte subset in FTY720-treated multiple sclerosis patients.

Johnson TA, Evans BL, Durafourt BA, Blain M, Lapierre Y, Bar-Or A, Antel JP.

J Immunol. 2011 Jul 1;187(1):570-9. doi: 10.4049/jimmunol.1003823. Epub 2011 May 27.

151.

Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels.

Nakashima I, Takahashi T, Cree BA, Kim HJ, Suzuki C, Genain CP, Vincent T, Fujihara K, Itoyama Y, Bar-Or A.

J Clin Neurosci. 2011 Jul;18(7):997-8. doi: 10.1016/j.jocn.2010.12.011. Epub 2011 May 11.

PMID:
21565508
152.

Treatment of multiple sclerosis with anti-CD20 antibodies.

Barun B, Bar-Or A.

Clin Immunol. 2012 Jan;142(1):31-7. doi: 10.1016/j.clim.2011.04.005. Epub 2011 Apr 15. Review.

PMID:
21555250
153.

Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study.

Banwell B, Bar-Or A, Arnold DL, Sadovnick D, Narayanan S, McGowan M, O'Mahony J, Magalhaes S, Hanwell H, Vieth R, Tellier R, Vincent T, Disanto G, Ebers G, Wambera K, Connolly MB, Yager J, Mah JK, Booth F, Sebire G, Callen D, Meaney B, Dilenge ME, Lortie A, Pohl D, Doja A, Venketaswaran S, Levin S, Macdonald EA, Meek D, Wood E, Lowry N, Buckley D, Yim C, Awuku M, Cooper P, Grand'maison F, Baird JB, Bhan V, Marrie RA.

Lancet Neurol. 2011 May;10(5):436-45. doi: 10.1016/S1474-4422(11)70045-X. Epub 2011 Mar 31.

PMID:
21459044
154.

Laquinimod in multiple sclerosis.

Giacomini PS, Bar-Or A.

Clin Immunol. 2012 Jan;142(1):38-43. doi: 10.1016/j.clim.2011.02.021. Epub 2011 Mar 4. Review.

PMID:
21450529
155.

Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.

Mehling M, Johnson TA, Antel J, Kappos L, Bar-Or A.

Neurology. 2011 Feb 22;76(8 Suppl 3):S20-7. doi: 10.1212/WNL.0b013e31820db341. Review.

PMID:
21339487
156.

HLA-DRB1 confers increased risk of pediatric-onset MS in children with acquired demyelination.

Disanto G, Magalhaes S, Handel AE, Morrison KM, Sadovnick AD, Ebers GC, Banwell B, Bar-Or A; Canadian Pediatric Demyelinating Disease Network.

Neurology. 2011 Mar 1;76(9):781-6. doi: 10.1212/WNL.0b013e31820ee1cd. Epub 2011 Feb 2.

157.

Mitochondrial DNA haplogroups and mutations in children with acquired central demyelination.

Venkateswaran S, Zheng K, Sacchetti M, Gagne D, Arnold DL, Sadovnick AD, Scherer SW, Banwell B, Bar-Or A, Simon DK; Canadian Pediatric Demyelinating Disease Network.

Neurology. 2011 Mar 1;76(9):774-80. doi: 10.1212/WNL.0b013e31820ee1bb. Epub 2011 Feb 2.

158.

Phase III dose-comparison study of glatiramer acetate for multiple sclerosis.

Comi G, Cohen JA, Arnold DL, Wynn D, Filippi M; FORTE Study Group.

Ann Neurol. 2011 Jan;69(1):75-82. doi: 10.1002/ana.22316.

PMID:
21280077
159.

Reduced thymic output and peripheral naïve CD4 T-cell alterations in primary progressive multiple sclerosis (PPMS).

Haegert DG, Hackenbroch JD, Duszczyszyn D, Fitz-Gerald L, Zastepa E, Mason H, Lapierre Y, Antel J, Bar-Or A.

J Neuroimmunol. 2011 Apr;233(1-2):233-9. doi: 10.1016/j.jneuroim.2010.12.007. Epub 2011 Jan 26.

PMID:
21272945
160.

Therapies for multiple sclerosis: considerations in the pediatric patient.

Banwell B, Bar-Or A, Giovannoni G, Dale RC, Tardieu M.

Nat Rev Neurol. 2011 Feb;7(2):109-22. doi: 10.1038/nrneurol.2010.198. Epub 2011 Jan 11. Review.

PMID:
21224883
161.

Strategy for anti-aquaporin-4 auto-antibody identification and quantification using a new cell-based assay.

De Vidi I, Boursier G, Delouche N, Portalès P, Cadars E, Bouthier M, Mettling C, Lin YL, Thouvenot E, Carlander B, Camu W, Antel JP, Bar-Or A, Zephir H, Vermersch P, De Seze J, Corbeau P, Eliaou JF, Vincent T.

Clin Immunol. 2011 Mar;138(3):239-46. doi: 10.1016/j.clim.2010.11.012. Epub 2010 Dec 28.

PMID:
21190899
162.

Distinct properties of circulating CD8+ T cells in FTY720-treated patients with multiple sclerosis.

Johnson TA, Lapierre Y, Bar-Or A, Antel JP.

Arch Neurol. 2010 Dec;67(12):1449-55. doi: 10.1001/archneurol.2010.312.

PMID:
21149809
163.

A proteome map of axoglial specializations isolated and purified from human central nervous system.

Dhaunchak AS, Huang JK, De Faria Junior O, Roth AD, Pedraza L, Antel JP, Bar-Or A, Colman DR.

Glia. 2010 Dec;58(16):1949-60. doi: 10.1002/glia.21064.

PMID:
20830807
164.

Differential responses of human microglia and blood-derived myeloid cells to FTY720.

Durafourt BA, Lambert C, Johnson TA, Blain M, Bar-Or A, Antel JP.

J Neuroimmunol. 2011 Jan;230(1-2):10-6. doi: 10.1016/j.jneuroim.2010.08.006. Epub 2010 Sep 9.

PMID:
20826007
165.

Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis.

Darlington PJ, Boivin MN, Renoux C, François M, Galipeau J, Freedman MS, Atkins HL, Cohen JA, Solchaga L, Bar-Or A.

Ann Neurol. 2010 Oct;68(4):540-5. doi: 10.1002/ana.22065.

PMID:
20661924
166.

Glatiramer acetate-reactive T lymphocytes regulate oligodendrocyte progenitor cell number in vitro: role of IGF-2.

Zhang Y, Jalili F, Ouamara N, Zameer A, Cosentino G, Mayne M, Hayardeny L, Antel JP, Bar-Or A, John GR.

J Neuroimmunol. 2010 Oct 8;227(1-2):71-9. doi: 10.1016/j.jneuroim.2010.06.014. Epub 2010 Jul 15.

167.

TLR-mediated B cell activation results in ectopic CLIP expression that promotes B cell-dependent inflammation.

Newell MK, Tobin RP, Cabrera JH, Sorensen MB, Huckstep A, Villalobos-Menuey EM, Burnett M, McCrea E, Harvey CP, Buddiga A, Bar-Or A, Freedman MS, Nalbantoglu J, Arbour N, Zamvil SS, Antel JP.

J Leukoc Biol. 2010 Oct;88(4):779-89. doi: 10.1189/jlb.0410237. Epub 2010 Jul 14. Erratum in: J Leukoc Biol. 2010 Dec;88(6):1279. J Leukoc Biol. 2010 Dec;88(6):1279.

168.

Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients.

Johnson TA, Shames I, Keezer M, Lapierre Y, Haegert DG, Bar-Or A, Antel J.

Clin Immunol. 2010 Oct;137(1):15-20. doi: 10.1016/j.clim.2010.06.005.

PMID:
20599429
169.

Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?

Bar-Or A, Fawaz L, Fan B, Darlington PJ, Rieger A, Ghorayeb C, Calabresi PA, Waubant E, Hauser SL, Zhang J, Smith CH.

Ann Neurol. 2010 Apr;67(4):452-61. doi: 10.1002/ana.21939.

PMID:
20437580
170.

A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis.

Burton JM, Kimball S, Vieth R, Bar-Or A, Dosch HM, Cheung R, Gagne D, D'Souza C, Ursell M, O'Connor P.

Neurology. 2010 Jun 8;74(23):1852-9. doi: 10.1212/WNL.0b013e3181e1cec2. Epub 2010 Apr 28. Erratum in: Neurology. 2010 Aug 3;75(5):480. Neurology. 2010 Sep 14;75(11):1029. Dosage error in article text.

171.

Anti-myelin antibodies modulate clinical expression of childhood multiple sclerosis.

O'Connor KC, Lopez-Amaya C, Gagne D, Lovato L, Moore-Odom NH, Kennedy J, Krupp L, Tenembaum S, Ness J, Belman A, Boyko A, Bykova O, Mah JK, Stoian CA, Waubant E, Kremenchutzky M, Ruggieri M, Bardini MR, Rensel M, Hahn J, Weinstock-Guttman B, Yeh EA, Farrell K, Freedman MS, Iivanainen M, Bhan V, Dilenge M, Hancock MA, Gano D, Fattahie R, Kopel L, Fournier AE, Moscarello M, Banwell B, Bar-Or A.

J Neuroimmunol. 2010 Jun;223(1-2):92-9. doi: 10.1016/j.jneuroim.2010.02.019. Epub 2010 Apr 8.

PMID:
20381173
172.

Chronic cerebrospinal venous insufficiency and multiple sclerosis.

Khan O, Filippi M, Freedman MS, Barkhof F, Dore-Duffy P, Lassmann H, Trapp B, Bar-Or A, Zak I, Siegel MJ, Lisak R.

Ann Neurol. 2010 Mar;67(3):286-90. doi: 10.1002/ana.22001.

PMID:
20373339
173.

EBV and brain matter(s)?

Ascherio A, Bar-Or A.

Neurology. 2010 Apr 6;74(14):1092-5. doi: 10.1212/WNL.0b013e3181dabfb5. Epub 2010 Mar 17. No abstract available.

PMID:
20237306
174.

The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group.

Freedman MS, Bar-Or A, Atkins HL, Karussis D, Frassoni F, Lazarus H, Scolding N, Slavin S, Le Blanc K, Uccelli A; MSCT Study Group.

Mult Scler. 2010 Apr;16(4):503-10. doi: 10.1177/1352458509359727. Epub 2010 Jan 19.

PMID:
20086020
175.

Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results.

Comi G, O'Connor P, Montalban X, Antel J, Radue EW, Karlsson G, Pohlmann H, Aradhye S, Kappos L; FTY720D2201 Study Group.

Mult Scler. 2010 Feb;16(2):197-207. doi: 10.1177/1352458509357065. Epub 2009 Dec 22.

PMID:
20028707
176.

Antigen-specific therapies in multiple sclerosis.

Giacomini PS, Bar-Or A.

Expert Opin Emerg Drugs. 2009 Sep;14(3):551-60. doi: 10.1517/14728210903203790. Review.

PMID:
19708820
177.

Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis.

McLaughlin KA, Chitnis T, Newcombe J, Franz B, Kennedy J, McArdel S, Kuhle J, Kappos L, Rostasy K, Pohl D, Gagne D, Ness JM, Tenembaum S, O'Connor KC, Viglietta V, Wong SJ, Tavakoli NP, de Seze J, Idrissova Z, Khoury SJ, Bar-Or A, Hafler DA, Banwell B, Wucherpfennig KW.

J Immunol. 2009 Sep 15;183(6):4067-76. doi: 10.4049/jimmunol.0801888. Epub 2009 Aug 17.

178.

Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression?

Bar-Or A, Oger J, Gibbs E, Niino M, Aziz T, Renoux C, Alatab S, Shi FD, Campagnolo D, Jalili F, Rhodes S, Yamashita T, Fan B, Freedman MS, Panitch H, Arnold DL, Vollmer T.

Mult Scler. 2009 Aug;15(8):959-64. doi: 10.1177/1352458509106230.

PMID:
19667022
179.

Fatigue in post-poliomyelitis syndrome: association with disease-related, behavioral, and psychosocial factors.

Trojan DA, Arnold DL, Shapiro S, Bar-Or A, Robinson A, Le Cruguel JP, Narayanan S, Tartaglia MC, Caramanos Z, Da Costa D.

PM R. 2009 May;1(5):442-9. doi: 10.1016/j.pmrj.2009.03.003.

PMID:
19627931
180.

Emerging multiple sclerosis disease-modifying therapies.

Giacomini PS, Darlington PJ, Bar-Or A.

Curr Opin Neurol. 2009 Jun;22(3):226-32. Review.

PMID:
19434781
181.

Myelin regulates immune cell adhesion and motility.

Pool M, Niino M, Rambaldi I, Robson K, Bar-Or A, Fournier AE.

Exp Neurol. 2009 Jun;217(2):371-7. doi: 10.1016/j.expneurol.2009.03.014. Epub 2009 Mar 27.

PMID:
19328785
182.

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study.

Goodman AD, Rossman H, Bar-Or A, Miller A, Miller DH, Schmierer K, Lublin F, Khan O, Bormann NM, Yang M, Panzara MA, Sandrock AW; GLANCE Investigators.

Neurology. 2009 Mar 3;72(9):806-12. doi: 10.1212/01.wnl.0000343880.13764.69.

183.

Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA.

Cree BA, Reich DE, Khan O, De Jager PL, Nakashima I, Takahashi T, Bar-Or A, Tong C, Hauser SL, Oksenberg JR.

Arch Neurol. 2009 Feb;66(2):226-33. doi: 10.1001/archneurol.2008.541.

184.

Incidence of acquired demyelination of the CNS in Canadian children.

Banwell B, Kennedy J, Sadovnick D, Arnold DL, Magalhaes S, Wambera K, Connolly MB, Yager J, Mah JK, Shah N, Sebire G, Meaney B, Dilenge ME, Lortie A, Whiting S, Doja A, Levin S, MacDonald EA, Meek D, Wood E, Lowry N, Buckley D, Yim C, Awuku M, Guimond C, Cooper P, Grand'Maison F, Baird JB, Bhan V, Bar-Or A.

Neurology. 2009 Jan 20;72(3):232-9. doi: 10.1212/01.wnl.0000339482.84392.bd.

PMID:
19153370
185.

Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much?

Giacomini PS, Arnold DL, Bar-Or A, Antel JP.

Arch Neurol. 2009 Jan;66(1):19-20. doi: 10.1001/archneurol.2008.529. No abstract available.

PMID:
19139295
186.

Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study.

O'Connor P, Comi G, Montalban X, Antel J, Radue EW, de Vera A, Pohlmann H, Kappos L; FTY720 D2201 Study Group.

Neurology. 2009 Jan 6;72(1):73-9. doi: 10.1212/01.wnl.0000338569.32367.3d.

PMID:
19122034
187.

Dendritic cell differentiation signals induce anti-inflammatory properties in human adult microglia.

Lambert C, Desbarats J, Arbour N, Hall JA, Olivier A, Bar-Or A, Antel JP.

J Immunol. 2008 Dec 15;181(12):8288-97.

188.

Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS.

Arnold DL, Campagnolo D, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, Vollmer T.

J Neurol. 2008 Oct;255(10):1473-8. doi: 10.1007/s00415-008-0911-x. Epub 2008 Oct 7.

PMID:
18854910
189.

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.

Mehling M, Brinkmann V, Antel J, Bar-Or A, Goebels N, Vedrine C, Kristofic C, Kuhle J, Lindberg RL, Kappos L.

Neurology. 2008 Oct 14;71(16):1261-7. doi: 10.1212/01.wnl.0000327609.57688.ea.

PMID:
18852441
190.

Cross-reactivity between epidemiology and immunology in multiple sclerosis.

Bar-Or A, Antel J.

Neurology. 2008 Oct 7;71(15):1132-3. doi: 10.1212/01.wnl.0000327519.19348.b4. No abstract available.

PMID:
18838660
191.

Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment.

Vincent T, Saikali P, Cayrol R, Roth AD, Bar-Or A, Prat A, Antel JP.

J Immunol. 2008 Oct 15;181(8):5730-7.

192.

The use of disease-modifying agents in multiple sclerosis--by the Canadian Network of MS Clinics.

O'Connor P, Devonshire V; Canadian Network of MS Clinic.

Can J Neurol Sci. 2008 May;35(2):127-32. English, French. No abstract available.

PMID:
18574923
193.

Innate immune-mediated neuronal injury consequent to loss of astrocytes.

Darlington PJ, Podjaski C, Horn KE, Costantino S, Blain M, Saikali P, Chen Z, Baker KA, Newcombe J, Freedman M, Wiseman PW, Bar-Or A, Kennedy TE, Antel JP.

J Neuropathol Exp Neurol. 2008 Jun;67(6):590-9. doi: 10.1097/NEN.0b013e3181772cf6.

PMID:
18520777
194.

B-cell-derived interleukin-10 in autoimmune disease: regulating the regulators.

Rieger A, Bar-Or A.

Nat Rev Immunol. 2008 Jun;8(6):486-7. doi: 10.1038/nri2315-c1. No abstract available.

PMID:
18500232
195.

Elevated serum inflammatory markers in post-poliomyelitis syndrome.

Fordyce CB, Gagne D, Jalili F, Alatab S, Arnold DL, Da Costa D, Sawoszczuk S, Bodner C, Shapiro S, Collet JP, Robinson A, Le Cruguel JP, Lapierre Y, Bar-Or A, Trojan DA.

J Neurol Sci. 2008 Aug 15;271(1-2):80-6. doi: 10.1016/j.jns.2008.03.015. Epub 2008 May 12.

PMID:
18474371
196.

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.

Vollmer T, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, Campagnolo D, Deutsch F, Arnold DL.

Mult Scler. 2008 Jun;14(5):663-70. doi: 10.1177/1352458507085759. Epub 2008 Apr 18.

PMID:
18424479
197.

Beta interferons in clinically isolated syndromes: a meta-analysis.

Melo A, Rodrigues B, Bar-Or A.

Arq Neuropsiquiatr. 2008 Mar;66(1):8-10. Review.

198.

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.

Bar-Or A, Calabresi PA, Arnold D, Markowitz C, Shafer S, Kasper LH, Waubant E, Gazda S, Fox RJ, Panzara M, Sarkar N, Agarwal S, Smith CH.

Ann Neurol. 2008 Mar;63(3):395-400. doi: 10.1002/ana.21363. Erratum in: Ann Neurol. 2008 Jun;63(6):803. Arnlod, Douglas [corrected to Arnold, Douglas].

PMID:
18383069
199.

Lesion distribution in children with clinically isolated syndromes.

Ghassemi R, Antel SB, Narayanan S, Francis SJ, Bar-Or A, Sadovnick AD, Banwell B, Arnold DL; Canadian Pediatric Demyelinating Disease Study Group.

Ann Neurol. 2008 Mar;63(3):401-5. doi: 10.1002/ana.21322.

PMID:
18306242
200.

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH; HERMES Trial Group.

N Engl J Med. 2008 Feb 14;358(7):676-88. doi: 10.1056/NEJMoa0706383.

Supplemental Content

Loading ...
Support Center